United States for the treatment of complicated urinary tract infections and, in conjunction with metronidazole, for intra-abdominal infections [1] . The in vitro spectrum of C/T's activity includes both susceptible and multidrug-resistant (MDR) strains of Pseudomonas aeruginosa. Farrell et al have reported that C/T is the most active commercially available anti-P. aeruginosa β-lactam antibiotic [2] .
With increasing resistance of P. aeruginosa isolates to antimicrobial agents such as β-lactams and fluoroquinolones as well as an aging population with increased risk of nephrotoxicity from other anti-P. aeruginosa drugs such as aminoglycosides and polymyxins, C/T offers an attractive option in the management of infections due to MDR P. aeruginosa.
Pseudomonas aeruginosa is a common cause of healthcare-associated pneumonia and ventilator-associated pneumonia [3] . We recently successfully used C/T in the treatment of 3 patients with pneumonia due to MDR P. aeruginosa. All patients were diagnosed using conventional criteria of fever, new pulmonary infiltrate on imaging, leukocytosis, and growth of P. aeruginosa in a culture of respiratory secretions. No patient was bacteremic. We dosed C/T at 3 g intravenously every 8 hours as is currently being studied in a clinical trial for ventilator-associated pneumonia [4] . Details of the 3 cases are summarized in Table 1 .
The choice of effective therapy for serious gram-negative infections is currently complicated by recurrent shortages of antibiotics. For example, supply shortages of piperacillin/tazobactam has led to, in our experience, an increased use of carbapenems. This raises a serious concern of stimulating the more rapid emergence of carbapenemresistant organisms. All 3 isolates from our patients demonstrated in vitro resistance to meropenem. Additionally, C/T offers an alternative to carbapenems when extended-spectrum β-lactamaseproducing organisms are suspected or documented [5, 6] .
Although C/T is not currently Food and Drug Administration approved for the treatment of pneumonia, increasing antimicrobial resistance among gramnegative organisms makes selection of therapy progressively difficult. Pending further information from ongoing clinical trials, we wanted to share our experience with this new agent for an off-label indication. 
